Literature DB >> 15646811

Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker.

Bela Bodey1, Vivian Bodey, Stuart E Siegel, Hans E Kaiser.   

Abstract

Survivin is a member of the inhibitor of apoptosis gene family that is expressed in embryonic tissues during human ontogenesis and most human malignancies, but it is not present in the majority of normal adult tissues. Survivin is also a chromosomal passenger protein required for physiological cell divison. Survivin blocks apoptosis, via its BIR domain, by either directly or indirectly blocking the function of the members of the caspase cascade. The expression of this apoptosis inhibitor protein in medulloblastomas (MEDs) was examined for the first time. During the immunohistochemical study, a sensitive, four-step, alkaline phosphatase conjugated antigen detection technique was employed. The results did, in fact, demonstrate the presence of survivin in 10 to 50 per cent of medulloblastoma (MED) cells with medium intensity immunoreactivity (++, B) in this neuroectodermal brain tumor. These results indicate that survivin is probably not only a diagnostic marker, but also an important prognostic marker for MEDs/PNETs and may be useful in the future grading of malignancy in MEDs, much as grading is done today for astrocytomas (ASTRs). Furthermore, the almost exclusive neoplastic expression of survivin will allow development of new antineoplastic, immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646811

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  6 in total

1.  Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.

Authors:  Smita K Nair; Timothy Driscoll; David Boczkowski; Robert Schmittling; Renee Reynolds; Laura A Johnson; Gerald Grant; Herbert Fuchs; Darell D Bigner; John H Sampson; Sridharan Gururangan; Duane A Mitchell
Journal:  J Neurooncol       Date:  2015-08-27       Impact factor: 4.130

2.  Lack of prognostic significance of survivin in pediatric medulloblastoma.

Authors:  Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

3.  Survivin expression in medulloblastoma: a possible marker for survival.

Authors:  Azza Abdel-Aziz; Mie Ali Ali Mohamed; Fatma Mohamed Farouk Akl; Ahmed Nageeb M Taha
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

Review 4.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

5.  Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.

Authors:  Don Eslin; Chris Lee; Umesh T Sankpal; Pius Maliakal; Robert M Sutphin; Liz Abraham; Riyaz Basha
Journal:  Tumour Biol       Date:  2013-05-18

Review 6.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.